Reports

Sale

Autism Spectrum Disorder Therapeutics Market

Global Autism Spectrum Disorder Therapeutics Market Size, Share, Growth, Statistics, Report, Analysis, Forecast: By Disease Type: Autistic Disorder, Asperger’s Syndrome, Pervasive Development Disorder (PDD), Others; By Treatment Type; By Age Group; By Distribution Channel; Regional Analysis; Marker Dynamics; Supplier Landscape; 2024-2032

Global Autism Spectrum Disorder Therapeutics Market Outlook

The global autism spectrum disorder therapeutics market size attained a value of USD 2.12 billion in 2023, driven by the rising occurrences of ASD, increasing research and development aided by the government and industrial players, and growing pipeline of ASD drugs. The market is anticipated to grow at a CAGR of 6.7% during the forecast period of 2024-2032 to attain a value of USD 3.81 billion by 2032.

 

autism-spectrum-disorder-therapeutics-market

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Demand for Communication and Behavioural Therapies to Augment the Market Growth of ASD Therapeutics

Based on treatment type, the communication and behavioural therapies segment is expected to account for a significant share in the autism spectrum disorder therapeutics market. There is no cure for ASD, however, certain behavioural therapies can help reduce and manage problematic symptoms. Behavioural and speech language therapies aid in developing the patient’s social skills. Applied Behaviour Analysis (ABA) helps children with ASD learn how to communicate and play while diminishing troublesome behaviours. Research has shown that long term behavioural therapies has positively impacted children as well as adults with ASD.

 

The North American Region to Hold Substantial Share in the Market for Autism Spectrum Disorder Therapeutics

North America is expected to hold a significant share of the autism spectrum disorder therapeutics market during the forecast period, supported by increased number of ASD cases in the region. In 2021, the U.S. Food and Drug Administration authorised the marketing of Cognoa ASD Diagnosis Aid, a device to help diagnose autism spectrum disorder (ASD). The region is also characterised by research and development in the field of ASD which is expected to propel market growth during the forecast period. For instance, the National Institute of Mental Health headquartered in the USA, supports research focussed on the treatment and outcomes of autism spectrum disorder and related disorders.

 

Market Segmentation

Autism spectrum disorder (ASD) is a neurological development disability characterised with conditions such as anxiety, depression, and attention-deficit, hyperactivity, among others. ASD can begin at infancy and last throughout adulthood through a person’s life. ASD can be diagnosed based on behavioural patterns. ASD treatments are focussed on reducing the factors that interfere with people’s orderly functioning. Some of the drugs prescribed by the U.S. FDA include Risperidone and Aripiprazole for treating irritability associated with ASD.

 

autism-spectrum-disorder-therapeutics-market-by-segmentation

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

By disease type, the market is divided into:

  • Autistic Disorder
  • Asperger’s Syndrome
  • Pervasive Developmental Disorder (PDD)
  • Others

Based on treatment type, the market can be segmented into:

  • Communication and Behavioural Therapies
    • Applied Behaviour Analysis (ABA) 
    • Speech and Language Therapy
    • Occupational Therapy
    • Others
  • Drug Therapies
    • Antipsychotic Drugs
    • Selective Serotonin Reuptake Inhibitors (SSRIs)
    • Stimulants
    • Sleep Medications
    • Others

The market is bifurcated based on age group into:

  • Child
  • Adult

On the basis of distribution channel, the market can be divided into:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

The regional markets for the product include North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.

 

autism-spectrum-disorder-therapeutics-market-by-region

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

 

Increasing Number of Pipeline Drugs and Investment in Research and Development for the Treatment of ASD Expected to Propel Market Growth

The forecast period is expected to witness the development of drugs to treat ASD. The presence of a growing pipeline of ASD drugs and increasing research and development in this field is expected to boost the autism spectrum disorder therapeutics market during the forecast period. In 2023, STALICLA, a Swiss clinical stage biotech company announced the completion of the phase 1b trials for STP1. The trials allow the application of the company’s precision medicine discovery platform in ASD.

Over the forecast period, the rising number of ASD patients and the increasing awareness regarding the disease along with rising governmental initiatives is expected to encourage research in this area. Further, rapid technological advancements in medicine are expected to favour the market growth during the forecast period. Moreover, the adoption of behavioural therapies to overcome the communication gap in such patients is expected to further aid the market growth.

 

Key Players in the Global Market for Autism Spectrum Disorder Therapeutics

The report gives a detailed analysis of the following key players in the global autism spectrum disorder therapeutics market, covering their competitive landscape, capacity, and latest developments like mergers, acquisitions, and investments, expansions of capacity, and plant turnarounds:

  • Neurim Pharmaceuticals, Inc.
  • Q BioMed Inc.
  • Hopebridge, LLC
  • Yamo Pharmaceuticals LLC
  • Curemark, LLC
  • Bristol - Myers Squibb Company
  • Merck & Co., Inc.
  • Novartis AG
  • Johnson & Johnson Services Inc.
  • Eli Lilly and Company
  • F. Hoffmann - La Roche Ltd.
  • Axial Therapeutics Inc.

The comprehensive EMR report provides an in-depth assessment of the market based on the Porter's five forces model along with giving a SWOT analysis.

 

Key Highlights of the Report

REPORT FEATURES DETAILS
Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease type
  • Treatment Type
  • Age Group
  • Distribution Channel
  • Region
Breakup by Disease type
  • Autistic Disorder
  • Asperger’s Syndrome
  • Pervasive Development Disorder (PDD)
  • Others
Breakup by Treatment Type
  • Communication and Behavioural Therapies
  • Drug Therapies
Breakup by Age Group
  • Child
  • Adult
  • Others
Breakup by Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Others
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model 
  • Key Demand Indicators
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends 
  • Value Chain Analysis
Supplier Landscape
  • Market Structure
  • Company Profiles
    • Financial Analysis
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Neurim Pharmaceuticals, Inc.
  • Q BioMed Inc.
  • Hopebridge, LLC
  • Yamo Pharmaceuticals LLC
  • Curemark, LLC
  • Bristol - Myers Squibb Company
  • Merck & Co., Inc.
  • Novartis AG
  • Johnson & Johnson Services Inc.
  • Eli Lilly and Company
  • F. Hoffmann - La Roche Ltd.
  • Axial Therapeutics Inc.

 

*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

1    Preface
    1.1    Objectives of the Study
    1.2    Key Assumptions
    1.3    Report Coverage – Key Segmentation and Scope 
    1.4    Research Methodology
2    Executive Summary
3    Autism Spectrum Overview

    3.1    Guidelines and Stages
    3.2    Pathophysiology
    3.3    Screening and Diagnosis
    3.4    Treatment Pathway 
4    Patient Profile
    4.1    Patient Profile Overview
    4.2    Patient Psychology and Emotional Impact Factors
    4.3    Risk Assessment and Treatment Success Rate
5    Autism Spectrum Disorder Epidemiology Analysis
    5.1    Epidemiology Overview (2016-2031)
    5.2    North America Autism Spectrum Epidemiology (2016-2031)
    5.3    Europe Autism Spectrum Epidemiology (2016-2031)
    5.4    Asia-Pacific Autism Spectrum Epidemiology (2016-2031)
    5.5    Latin America Autism Spectrum Epidemiology (2016-2031)
    5.6    Middle East & Africa Autism Spectrum Epidemiology (2016-2031)
6    Global Autism Spectrum Disorder Treatment Market Overview 
    6.1    Global Autism Spectrum Disorder Treatment Market Historical Value (2017-2023) 
    6.2    Global Autism Spectrum Disorder Treatment Market Forecast Value (2024-2032)
7    Global Autism Spectrum Disorder Treatment Market Landscape
    7.1    Autism Spectrum Disorder Treatment: Developers Landscape
        7.1.1    Analysis by Year of Establishment
        7.1.2    Analysis by Company Size
        7.1.3    Analysis by Region
    7.2    Autism Spectrum Disorder Treatment: Product Landscape
        7.2.1    Analysis by Disease Type
        7.2.2    Analysis by Treatment Type
        7.2.3    Analysis by Age Group
        7.2.4    Analysis by Distribution Channel    
8    Autism Spectrum Disorder Treatment Challenges and Unmet Needs
    8.1    Treatment Pathway Challenges
    8.2    Compliance and Drop-Out Analysis
    8.3    Awareness and Prevention Gaps
9    Cost of Treatment
10    Global Autism Spectrum Disorder Treatment Market Dynamics

    10.1    Market Drivers and Constraints
    10.2    SWOT Analysis
    10.3    Porter’s Five Forces Model
    10.4    Key Demand Indicators 
    10.5    Key Price Indicators
    10.6    Industry Events, Initiatives, and Trends  
    10.7    Value Chain Analysis
11    Global Autism Spectrum Disorder Treatment Market Segmentation
    11.1    Global Autism Spectrum Disorder Treatment Market by Disease type
        11.1.1    Market Overview
        11.1.2    Autistic Disorder
        11.1.3    Asperger’s Syndrome
        11.1.4    Pervasive Development Disorder (PDD)
        11.1.5    Others
    11.2    Global Autism Spectrum Disorder Treatment Market by Treatment Type
        11.2.1    Market Overview
        11.2.2    Communication and Behavioural Therapies
            11.2.2.1    Applied Behaviour Analysis (ABA)
            11.2.2.2    Speech and Language Therapy
            11.2.2.3    Occupational Therapy
            11.2.2.4    Others
        11.2.3    Drug Therapies
            11.2.3.1    Antipsychotic Drugs
            11.2.3.2    Selective Serotonin Reuptake Inhibitors (SSRIs)
            11.2.3.3    Stimulants
            11.2.3.4    Sleep Medications
            11.2.3.5    Others
    11.3    Global Autism Spectrum Disorder Treatment Market by Age Group
        11.3.1    Market Overview
        11.3.2    Child
        11.3.3    Adult
        11.3.4    Others
    11.4    Global Autism Spectrum Disorder Treatment Market by Distribution Channel
        11.4.1    Market Overview
        11.4.2    Hospital Pharmacies
        11.4.3    Retail Pharmacies
        11.4.4    Online Pharmacies
        11.4.5    Others
    11.5    Global Autism Spectrum Disorder Treatment Market by Region
        11.5.1    Market Overview
        11.5.2    North America
        11.5.3    Europe 
        11.5.4    Asia Pacific
        11.5.5    Latin America
        11.5.6    Middle East and Africa
12    North America Autism Spectrum Disorder Treatment Market
    12.1    Market Share by Country
    12.2    United States of America
    12.3    Canada
13    Europe Autism Spectrum Disorder Treatment Market
    13.1    Market Share by Country
    13.2    United Kingdom
    13.3    Germany
    13.4    France
    13.5    Italy
    13.6    Others
14    Asia Pacific Autism Spectrum Disorder Treatment Market
    14.1    Market Share by Country
    14.2    China
    14.3    Japan
    14.4    India
    14.5    ASEAN
    14.6    Australia
    14.7    Others
15    Latin America Autism Spectrum Disorder Treatment Market
    15.1    Market Share by Country
    15.2    Brazil
    15.3    Argentina
    15.4    Mexico
    15.5    Others
16    Middle East and Africa Autism Spectrum Disorder Treatment Market
    16.1    Market Share by Country
    16.2    Saudi Arabia
    16.3    United Arab Emirates
    16.4    Nigeria
    16.5    South Africa
    16.6    Others
17    Regulatory Framework
    17.1    Regulatory Overview
        17.1.1    US FDA
        17.1.2    EU EMA
        17.1.3    INDIA CDSCO
        17.1.4    JAPAN PMDA
        17.1.5    Others
18    Patent Analysis
    18.1    Analysis by Type of Patent
    18.2    Analysis by Publication year
    18.3    Analysis by Issuing Authority
    18.4    Analysis by Patent Age
    18.5    Analysis by CPC Analysis
    18.6    Analysis by Patent Valuation 
    18.7    Analysis by Key Players
19    Grants Analysis
    19.1    Analysis by year
    19.2    Analysis by Amount Awarded
    19.3    Analysis by Issuing Authority
    19.4    Analysis by Grant Application
    19.5    Analysis by Funding Institute
    19.6    Analysis by NIH Departments
    19.7    Analysis by Recipient Organization 
20    Clinical Trials Analysis
    20.1     Analysis by Trial Registration Year
    20.2    Analysis by Trial Status
    20.3    Analysis by Trial Phase
    20.4    Analysis by Therapeutic Area
    20.5    Analysis by Geography
21    Funding and Investment Analysis
    21.1    Analysis by Funding Instances
    21.2    Analysis by Type of Funding
    21.3    Analysis by Funding Amount
    21.4    Analysis by Leading Players
    21.5    Analysis by Leading Investors
    21.6    Analysis by Geography
22    Partnership and Collaborations Analysis
    22.1    Analysis by Partnership Instances
    22.2    Analysis by Type of Partnership
    22.3    Analysis by Leading Players
    22.4    Analysis by Geography
23    Supplier Landscape
    23.1    Neurim Pharmaceuticals, Inc.
        23.1.1    Financial Analysis
        23.1.2    Product Portfolio
        23.1.3    Demographic Reach and Achievements
        23.1.4    Mergers and Acquisitions
        23.1.5    Certifications
    23.2    Q BioMed Inc.
        23.2.1    Financial Analysis
        23.2.2    Product Portfolio
        23.2.3    Demographic Reach and Achievements
        23.2.4    Mergers and Acquisitions
        23.2.5    Certifications
    23.3    Hopebridge, LLC
        23.3.1    Financial Analysis
        23.3.2    Product Portfolio
        23.3.3    Demographic Reach and Achievements
        23.3.4    Mergers and Acquisitions
        23.3.5    Certifications
    23.4    Yamo Pharmaceuticals LLC 
        23.4.1    Financial Analysis
        23.4.2    Product Portfolio
        23.4.3    Demographic Reach and Achievements
        23.4.4    Mergers and Acquisitions
        23.4.5    Certifications
    23.5    Curemark, LLC
        23.5.1    Financial Analysis
        23.5.2    Product Portfolio
        23.5.3    Demographic Reach and Achievements
        23.5.4    Mergers and Acquisitions
        23.5.5    Certifications
    23.6    Bristol - Myers Squibb Company
        23.6.1    Financial Analysis
        23.6.2    Product Portfolio
        23.6.3    Demographic Reach and Achievements
        23.6.4    Mergers and Acquisitions
        23.6.5    Certifications
    23.7    Merck & Co., Inc.
        23.7.1    Financial Analysis
        23.7.2    Product Portfolio
        23.7.3    Demographic Reach and Achievements
        23.7.4    Mergers and Acquisitions
        23.7.5    Certifications
    23.8    Novartis AG
        23.8.1    Financial Analysis
        23.8.2    Product Portfolio
        23.8.3    Demographic Reach and Achievements
        23.8.4    Mergers and Acquisitions
        23.8.5    Certifications
    23.9    Johnson & Johnson Services Inc.
        23.9.1    Financial Analysis
        23.9.2    Product Portfolio
        23.9.3    Demographic Reach and Achievements
        23.9.4    Mergers and Acquisitions
        23.9.5    Certifications
    23.10    Eli Lilly and Company
        23.10.1    Financial Analysis
        23.10.2    Product Portfolio
        23.10.3    Demographic Reach and Achievements
        23.10.4    Mergers and Acquisitions
        23.10.5    Certifications
    23.11    F. Hoffmann - La Roche Ltd.
        23.11.1    Financial Analysis
        23.11.2    Product Portfolio
        23.11.3    Demographic Reach and Achievements
        23.11.4    Mergers and Acquisitions
        23.11.5    Certifications
    23.12    Axial Therapeutics Inc.
        23.12.1    Financial Analysis
        23.12.2    Product Portfolio
        23.12.3    Demographic Reach and Achievements
        23.12.4    Mergers and Acquisitions
        23.12.5    Certifications
    23.13    Others
24    Autism Spectrum Disorder Treatment - Distribution Model (Additional Insight)
    24.1    Overview 
    24.2    Potential Distributors 
    24.3    Key Parameters for Distribution Partner Assessment 
25    Key Opinion Leaders (KOL) Insights (Additional Insight)
26    Company Competitiveness Analysis (Additional Insight)

    26.1    Very Small Companies
    26.2    Small Companies
    26.3    Mid-Sized Companies
    26.4    Large Companies
    26.5    Very Large Companies
27    Payment Methods (Additional Insight)
    27.1    Government Funded
    27.2    Private Insurance
    27.3    Out-of-Pocket

 

*Additional insights provided are customisable as per client requirements.

Key Questions Answered in the Report

In 2023, the global market for Autism Spectrum Disorder Therapeutics reached a value of USD 2.12 billion.

The market is anticipated to grow at a CAGR of 6.7% during the forecast period of 2024-2032 to reach a value of USD 3.81 billion by 2032.

The major drivers of the industry, such as the rising occurrences of ASD, increasing research and development aided by the government and industrial players, growing pipeline of ASD drugs, and rising focus on behavioural therapies, are expected to aid the market growth.

The key market trends include the increasing research and development to produce ASD drugs and rising awareness regarding ASD and its treatment.

The major regions in the market are North America, Latin America, the Middle East and Africa, Europe, and the Asia Pacific.

The disease types covered in the report include autistic disorder, Asperger’s syndrome, and pervasive developmental disorder (PDD), among others.

The market is divided, based on treatment type, into communication and behavioural therapies and drug therapies.

The age groups considered in the market report include child and adult.

The various distribution channels in the market are hospital pharmacies, retail pharmacies, and online pharmacies.

Neurim Pharmaceuticals, Inc., Q BioMed Inc., Hopebridge, LLC, Yamo Pharmaceuticals LLC, Curemark, LLC, Bristol - Myers Squibb Company, Merck & Co., Inc., Novartis AG, Johnson & Johnson Services Inc., Eli Lilly and Company, F. Hoffmann - La Roche Ltd., and Axial Therapeutics Inc., among others.

Purchase Full Report

Mini Report

$ 3499     $2999
  • Selected Sections, One User
  • Printing Not Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Single User License

$ 5999     $5499
  • All Sections, One User
  • One Print Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update
most popular

Five User License

$ 8299     $7499
  • All Sections, Five Users
  • Five Prints Allowed
  • Email Delivery in PDF
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Corporate License

$ 10499     $9499
  • All Sections, Unlimited Users
  • Unlimited Prints Allowed
  • Email Delivery in PDF + Excel
  • Free Limited Customisation
  • Post Sales Analyst Support
  • 50% Discount on Next Update

Any Question? Speak With An Analyst

Contact Analyst

View A Sample

Request Sample

Did You Miss Anything, Ask Now

Request Customisation
Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.

NEWSLETTER